We demonstrate that most gliosarcoma tumors have somatic alterations of PIK3/Akt (PTEN, PI3K) and RAS/MAPK (NF1, BRAF) signaling pathways that are crucial for tumor growth and therapy resistance. This evidence concerns the gene AKT1 and neoplasm.